Asthma, COPD, Lung Cancer News | Treatment & Research Articles
The 2025 GOLD COPD report includes a new emphasis on CV disease and PH in COPD and major updates on spirometry, new COPD drugs, climate change, and more.
GOLD COPD Report 2025: Key Spirometry and Drug Updates
2024年11月22日 · The 2025 GOLD COPD report includes a new emphasis on CV disease and PH in COPD and major updates on spirometry, new COPD drugs, climate change, and more. The Global Initiative for Chronic Obstructive Lung Disease (GOLD) released its 2025 updated version of the GOLD Chronic Obstructive Pulmonary ...
COPD Triple Therapy vs LABA/LAMA May Increase Risk for …
5 天之前 · Patients who switched to triple therapy for chronic obstructive pulmonary disease (COPD) after treatment with long-acting beta2-agonists/inhaled corticosteroids (LABA/ICS) had a higher risk for severe pneumonia and death than patients who switched to dual bronchodilators, according to study findings published in Therapeutic Advances in Respiratory Disease.
GINA 2024 Asthma Update: Revised Recommendations on …
2024年6月28日 · The GINA 2024 asthma update includes new guidance on medications, monitoring, treatment goals, remission, cough variant asthma, children, and more.
2024 GOLD Report Reflects New Research on COPD Management
2023年12月8日 · The 2024 GOLD Report, “Global Strategy for Prevention Diagnosis and Management of COPD,” not only includes guideline updates that reflect the latest research on chronic obstructive pulmonary disease (COPD); it also reflects some shifts in thinking about what’s important in COPD treatment, according to Claus Vogelmeier, MD, a lead report author and science committee chair for the Global ...
Ensacove Approved for ALK-Positive Locally Advanced or …
2 天之前 · The Food and Drug Administration (FDA) has approved Ensacove (ensartinib) for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive locally advanced or metastatic non-small cell lung cancer (NSCLC) who have not previously received an ALK inhibitor.The approval was based on data from the randomized, phase 3 eXalt3 study (ClinicalTrials.gov Identifier: NCT02767804 ...
News Archive - Pulmonology Advisor
5 天之前 · Researchers compared COPD outcomes in patients who switched to triple therapy (LABA/LAMA/ICS) vs dual bronchodilators (LABA/LAMA) after using LABA/ICS.
Dupixent Approved as Add-On Maintenance Therapy in COPD
2024年10月1日 · The Food and Drug Administration (FDA) has approved Dupixent (dupilumab) as an add-on maintenance therapy for adults with inadequately controlled chronic obstructive pulmonary disease (COPD) and an eosinophilic phenotype.. The approval was supported by data from the randomized, double-blind, multicenter, parallel-group, placebo-controlled, phase 3 trials BOREAS (ClinicalTrials.gov Identifier ...
Updated 2023 GOLD Report Revises COPD Definitions and …
2023年1月20日 · The 2023 report from the Global Initiative for Chronic Obstructive Lung Disease (GOLD) — “Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease” (COPD) 1 — details “an expanded range of therapies for COPD that now can be considered to improve mortality,” according to Gerard J. Criner, MD, FACP, FACCP, an author of the 2023 GOLD ...
Treating Severe Uncontrolled Asthma: Can Single-Inhaler, Fixed …
In everyday clinical practice, stratifying patients with asthma using specific clinical features and biomarkers, as summarized in Table 1, allocates most patients to either allergic-predominant or eosinophilic-predominant T2-high asthma to allow selection of appropriate treatment. 4 For example, the anti-IgE agent omalizumab is the treatment of choice for a …